NEW YORK (GenomeWeb) – Startup microbiome-based technology firm Enterome said today that it raised €10 million ($13.9 million) in the first tranche of a Series B financing round.

The Paris-based company said that the funding will be used to conduct R&D and business activities. Its technology platform, called the Metagenotyping system, is for developing new tools, such as biomarkers and companion diagnostics, for managing diseases. Eventually, the platform will be used for developing therapeutics for inflammatory bowel and metabolic disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.